LexDanaLexDanabeta
Inventor

Paul A. Moore

Inventor
Germantown, MD, US

Overview

63→
Patents
1997–2020
Patent span
Chemistry
Primary field (CPC C)

Patents· 63 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Kprimary
C07KPeptides29%
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations17%
G01NInvestigating or analysing materials by determining their chemical or physical properties10%
C12NMicroorganisms or enzymes8%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms3%
C07HSugars2%
C10MLubricating compositions1%
Y02ATechnologies for adaptation to climate change1%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests1%
PatentTitleYear
10,858,430Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof202010,787,521Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof202010,730,945Antibodies reactive with B7-H3 and users thereof202010,683,364Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof202010,647,768Multi-chain polypeptide-containing tri-specific binding molecules202010,633,443Bi-specific monovalent diabodies that are capable of binding CD19 and CD3, and uses thereof202010,633,440Multi-chain polypeptide-containing tri-specific binding molecules that specifically bind to multiple cancer antigens202010,577,422PD-1-binding molecules and methods of use thereof202010,501,552Multivalent molecules comprising DR5-binding domains201910,344,092Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof201910,160,806Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereof20189,932,400Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof20189,896,508'Antibodies reactive with B7-H3 and uses thereof'20189,884,921'Bispecific heterodimeric diabodies and uses thereof'20189,822,181'Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof'20179,714,295'Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof'20179,714,296'Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof'20179,441,049'Antibodies reactive with B7-H3 and uses thereof'20169,150,656'Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof'20158,802,091'Antibodies reactive with B7-H3 and uses thereof'20148,524,238'Cancer targets and uses thereof'20138,486,392'Methods and compositions for diagnosing and treating diseases'20138,372,948'12 human secreted proteins'20138,168,586'Cancer targets and uses thereof'20128,143,026'Albumin fusion proteins'20127,968,689'Antibodies to HSDEK49 polypeptides'20117,842,291'Methods and compositions for diagnosing and treating diseases'20107,816,091'Method of identifying a binding partner to a cytokine receptor common gamma chain like polypeptide'20107,504,105'Treatment using antibodies to cytokine receptor common gamma chain like'20097,459,531'50 Human secreted proteins'20087,390,637'Keratinocyte derived interferon'20087,335,489'Polynucleotides encoding a protein kinase C inhibitor protein and methods of using these polynucleotides'20087,247,442'Antibodies to HHPEN62 polypeptide'20077,232,667'Keratinocyte growth factor-2 polynucleotides'20077,205,139'Tissue plasminogen activator-like protease'20076,982,320'Cytokine receptor common gamma chain like'20066,953,667'Antibodies against human protein HUVDJ43'20056,936,691'Secreted protein HCE3C63'20056,919,433'Antibodies to protein HPMBQ91'20056,916,786'Keratinocyte growth factor-2'20056,914,047'Secreted protein HEMAE80'20056,903,072'Keratinocyte growth factor-2'20056,861,227'Antibodies to cytokine receptor common gamma chain like'20056,844,170'Cytokine receptor common gamma chain like'20056,815,534'Tissue plasminogen activator-like protease'20046,693,077'Keratinocyte growth factor-2'20046,639,052'Human ADA2 polypeptides'20036,627,741'Antibodies to secreted protein HCEJQ69'20036,605,592'Protein HOFNF53'20036,569,992'Protein HLQDR48'20036,566,325'49 human secreted proteins'20036,534,631'Secreted protein HT5GJ57'20036,525,174'Precerebellin-like protein'20036,475,753'94 Human Secreted Proteins'20026,476,195'Secreted protein HNFGF20'20026,472,512'Keratinocyte derived interferon'20026,433,145'Keratinocyte derived interferon'20026,420,526'186 human secreted proteins'20026,372,473'Tissue plasminogen activator-like protease'20026,344,543'Human transcription factor IIA'20026,077,692'Keratinocyte growth factor-2'20006,054,289'Polynucleotides encoding human ADA2'20005,652,117'Human transcription factor IIA'1997

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1997–2013Patents assigned to HUMAN GENOME SCIENCES INC (39)· patent assignee history
1997–2008Based in Germantown, MD, US· patent location history
2000–2003Based in Aberdeen, GB· patent location history
2004–2020Based in North Bethesda, MD, US· patent location history
2010–2013Patents assigned to CELERA CORP (4)· patent assignee history
2012–2015Patents assigned to MOORE PAUL A (4)· patent assignee history
2012–2013Patents assigned to MOORE PAUL (3)· patent assignee history
2012–2020Based in Bethesda, MD, US· patent location history
2014–2020Patents assigned to MACROGENICS INC (19)· patent assignee history
2018–2020Based in North Potomac, MD, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
HUMAN GENOME SCIENCES INC391997–2013
MACROGENICS INC192014–2020
CELERA CORP42010–2013
MOORE PAUL Aself42012–2015
MOORE PAULself32012–2013
Locations
LocationPatentsSpan
Germantown, Maryland, US271997–2008
North Bethesda, Maryland, US202004–2020
North Potomac, Maryland, US82018–2020
Bethesda, Maryland, US62012–2020
Aberdeen, GB22000–2003